IMP-17 is under clinical development by Eikon Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IMP-17’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IMP-17 is under development for the treatment of solid tumors. It acts by targeting Poly (ADP-Ribose) Polymerase 1.
Eikon Therapeutics overview
Eikon Therapeutics is a clinical-stage biotechnology company that carries out drug discovery and development. The company provides preclinical programs in the fields of oncology, neuroscience and immunology as well as clinic programs designed to improve cancer treatment. Its oncological pipeline products include TLR7/8 – BDB001 and PARP1 selective inhibitors – IMP1734 and IMP17307. The company utilizes technology such as single molecule tracking and super-resolution fluorescence microscopy the interface of biology, engineering and chemistry to discover novel treatments for life-threatening diseases. Eikon Therapeutics is headquartered in Hayward, California, the US.
For a complete picture of IMP-17’s drug-specific PTSR and LoA scores, buy the report here.